Inhibrx Biosciences vs Longeveron
Inhibrx Biosciences and Longeveron are similar in size: $1.3m and $1.2m of revenue in their latest fiscal years. Inhibrx Biosciences grew faster (550.0% against -49.9%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -10773.5%. Longeveron carries less debt relative to equity (0.0% against 1258.1%).
| Latest fiscal year | Inhibrx BiosciencesINBX, 2025 | LongeveronLGVN, 2025 |
|---|---|---|
| Revenue | $1.3m | $1.2m |
| Revenue growth | 550.0% | -49.9% |
| Net income | −$140m | −$22.7m |
| Operating margin | -10386.5% | -1942.2% |
| Net margin | -10773.5% | -1893.6% |
| Return on equity | -197.8% | -164.7% |
| Free cash flow | −$130m | −$18.9m |
| Cash | $124m | $4.7m |
| Total debt | $101m | $0 |
| Debt to equity | 1258.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 110 | 37 |
| Market value | $1.21bn | $55.5m |
| Price vs our value range | — | — |
| Moat score | — | 19 (Weak) |
| Insider trades, 12 months | 19 buys, 5 sales | 0 buys, 0 sales |